Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452854 · ClinicalTrials.gov registry record
Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
A clinical trial, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- 2
- Enrollment target
NCT01452854 is a clinical trial that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 2 participants.
The verdict
NCT01452854 was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade Glioma (LGG). It is important to know if different patient factors and Temozolomide influence the rate of ovarian aging in women with LGG who have good long-term survival rates. This will allow better counseling about the effects of this particular chemotherapy agent on fertility in women.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01452854
The ClinicalTrials.gov registry entry for NCT01452854 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01452854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01452854 about?
NCT01452854 is a clinical study titled "Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide". The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade Glioma (LGG). It is important to know if different patient factors and Te...
What is the current status of trial NCT01452854?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2011-10. Estimated completion is 2013-11.
Who is sponsoring clinical trial NCT01452854?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.